Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,339 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of D-0120 to Evaluate Safety and PK/PD Study in Healthy Volunteers

NCT04097405
View directory record Official record
Conditions
Healthy Volunteers
Interventions
D-0120, Placebo oral tablet
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

NCT07108153
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
SION-719, Placebo-to-match SION-719
Drug
Lead sponsor
Sionna Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Iowa City, Iowa • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 15, 2026, 9:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

NCT01362803
View directory record Official record
Conditions
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1, Neurofibroma, Plexiform
Interventions
AZD6244
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2032
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

NCT02520427
View directory record Official record
Conditions
Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
Interventions
AMG 330
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Duarte, California • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Results available

Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone

NCT01637922
View directory record Official record
Conditions
Hepatitis C
Interventions
BI 201335
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 64 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Atlanta, Georgia • Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Results available

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

NCT01438853
View directory record Official record
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
TNX-832, Placebo
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497
View directory record Official record
Conditions
Locally Advanced / Metastatic Solid Tumors
Interventions
CR-001
Drug
Lead sponsor
Crescent Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Galcanezumab in Healthy Participants.

NCT02836613
View directory record Official record
Conditions
Healthy
Interventions
Galcanezumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

NCT02121483
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
10 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Toledo, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD

NCT04882124
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Andalusia, Alabama • Crowley, Louisiana • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 15, 2026, 9:05 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

NCT06388083
View directory record Official record
Conditions
STGD1, Stargardt Disease 1
Interventions
Tinlarebant, Placebo
Drug
Lead sponsor
Belite Bio, Inc
Industry
Eligibility
12 Years to 20 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating PRA-027 Multiple Ascending Doses In Cycling And Postmenopausal Women

NCT00543790
View directory record Official record
Conditions
Uterine Leiomyomata (Fibroids)
Interventions
PRA-027
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Beverly Hills, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2010 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

NCT02987829
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Interventions
TRC253
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 15, 2026, 9:05 AM EDT
Terminated Phase 1 Interventional Results available

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

NCT03166631
View directory record Official record
Conditions
Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung
Interventions
BI 891065, BI 754091
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

NCT00774553
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

NCT02070939
View directory record Official record
Conditions
Healthy
Interventions
PF-06260414, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential

NCT00427544
View directory record Official record
Conditions
Fibroid
Interventions
PRA-027
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting Phase 1 Interventional

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

NCT07021898
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
ERAS-4001, ERAS-4001 in combination
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Nashville, Tennessee • Houston, Texas • Irving, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 15, 2026, 9:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

NCT05731947
View directory record Official record
Conditions
Colorectal Cancer, Solid Tumors
Interventions
Revumenib, Chemotherapy
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed No phase listed Observational

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

NCT00040729
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
mutation analysis
Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 15, 2026, 9:05 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

NCT04005807
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BPN-14967, Placebo
Drug
Lead sponsor
Belite Bio, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 15, 2026, 9:05 AM EDT